33 completed, 4 unknown, 2 terminated, 1 active not recruiting. 11 Phase 3, 10 Phase 2, 9 Phase 4, 5 Phase 1, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 10, Unknown 1 |
| Phase 2 | 10 | Completed 9, Terminated 1 |
| Phase 4 | 9 | Completed 6, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 5 |
| Not applicable | 4 | Completed 2, Unknown 2 |
Follow Tolterodine: new trials by email Literature Review of Tolterodine trials Research Report on Tolterodine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron Tolterodine, Mirabegron (beta3-adrenoceptor agonist) - Overactive Bladder (OAB), Premature (Early) Ejaculation | Completed | Başakşehir Çam & Sakura City Hospital | 40 | 2026-01-15 | 2026-08-13 | |
| Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study tolterodine, mirabegron, tolterodine , mirabegron - Female Patients With Overactive Bladder Syndrome | Phase 4 | Unknown | Far Eastern Memorial Hospital | 150 | 2023-09-12 | 2023-09-13 |
| Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After Surgery surgery, sacral neuromodulation, botulinum toxin A injection - Spinal Vascular Disorder Nos, Overactive Bladder | Not applicable | Unknown | Xuanwu Hospital, Beijing | 100 | 2023-01-01 | 2020-04-29 |
| Treatment of Overactive Bladder With Anticholinergic Agents Oxybutynin Cl, propiverine, Tolterodine - Overactive Bladder | Active not recruiting | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | 120 | 2022-09-01 | 2025-07-01 | |
| Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 5589 | 2018-07-20 | 2024-10-16 | |
| A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 805 | 2018-07-19 | 2020-04-22 | |
| Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. Uritos®, Urotol® - Overactive Bladder | Phase 3 | Completed | R-Pharm | 300 | 2016-07-18 | 2019-05-21 |
| the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery transvaginal synthetic mesh, Tolterodine - Pelvic Organ Prolapse | Phase 3 | Unknown | Peking University People's Hospital | 1000 | 2015-08-01 | 2017-05-23 |
| Genetic Determinants of Amitriptyline Efficiency for Pain Treatment Amitriptyline, Tolterodine - Chronic Pain | Phase 4 | Completed | Insel Gruppe AG, University Hospital Bern | 48 | 2014-11-01 | 2019-01-24 |
| Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II Amitriptyline, Tolterodine - Chronic Pain | Phase 4 | Completed | Insel Gruppe AG, University Hospital Bern | 48 | 2014-11-01 | 2019-01-24 |
| Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine tolterodine, mirabegron - Pharmacokinetics of Mirabegron and Tolterodine, Healthy | Phase 4 | Completed | Astellas Pharma Inc | 24 | 2013-06-01 | 2013-10-17 |
| Study of Herbmed Plus in Ureteral Stent Discomfort Herbmed plus, Placebo, Tolterodine - Ureteral Stent Discomfort | Phase 2 | Completed | Dr .S.B.PATANKAR | 140 | 2012-04-01 | 2016-01-05 |
| The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms Placebo, Terazosine, Tolterodine - Disorder of Urinary Stent | Phase 2 / Phase 3 | Completed | Urmia University of Medical Sciences | 104 | 2012-01-01 | 2015-03-02 |
| Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio) Oxycodone 15mg, Clobazam, Imipramine - Low Back Pain | Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 150 | 2010-07-01 | 2016-04-06 |
| GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation Clonazepam, Tolterodine, clobazam - Neuropathic Pain | Phase 1 / Phase 2 | Completed | University Hospital, Geneva | 25 | 2010-04-01 | 2011-12-14 |
| Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers clobazam, clonazepam, tolterodine - Pain | Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 17 | 2009-12-01 | 2010-08-11 |
| Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects Tolterodine, Pilocarpine, THVD-201 - Incontinence | Phase 1 | Completed | TheraVida, Inc. | 18 | 2009-09-01 | 2015-12-30 |
| Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis tolterodine, tamsulosin, placebo - Prostatitis | Not applicable | Unknown | Chongqing Medical University | 30 | 2009-08-01 | 2009-06-05 |
| A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder YM178, Placebo, tolterodine - Urinary Bladder, Overactive | Phase 3 | Completed | Astellas Pharma Inc | 1139 | 2009-07-24 | 2024-10-31 |
| Study of ONO-8539 in Patients With Overactive Bladder Placebo, Tolterodine, ONO-8539 - Overactive Bladder | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 435 | 2009-04-01 | 2012-06-14 |
Showing 20 of 41. Sign in to see all of them.
Urinary Bladder, Overactive (25) · Urinary Incontinence, Urge (11) · Urinary Incontinence (9) · Chronic Pain (2) · Low Back Pain (1) · Neuralgia (1) · Nocturia (1) · Pain (1) · Pelvic Organ Prolapse (1) · Premature Birth (1) · Prostatitis (1) · Sleep Wake Disorders (1) · Urinary Incontinence, Stress (1)
Astellas Pharma Inc (6) · Insel Gruppe AG, University Hospital Bern (4) · Astellas Pharma Singapore Pte. Ltd. (2) · Novartis (2) · Sanofi (2) · Assuta Hospital Systems (1) · Astellas Pharma Europe B.V. (1) · Başakşehir Çam & Sakura City Hospital (1) · Brigham and Women's Hospital (1) · Carelon Research (1) · Chongqing Medical University (1) · Dr .S.B.PATANKAR (1) · Far Eastern Memorial Hospital (1) · Imperial College London (1) · Inje University (1)
United States (9) · Switzerland (8) · Czechia (7) · Germany (7) · Sweden (7) · United Kingdom (6) · Netherlands (5) · Russia (5) · Belgium (4) · France (4) · Hungary (4) · Norway (4) · Poland (4) · Slovakia (4) · Spain (4)
Pascal H Vuilleumier, MD (2) · Ulrike Stamer, Professor (2) · Ali Tehranchi, Urologist (1) · Andreas Siegenthaler, Dr Med (1) · Jae-Gook Shin, MD, PhD (1) · Jianliu Wang, professor (1) · Joanne Marjason (1) · Kyu-Sung Lee, Ph.D (1) · Martin Michel, Prof. (1)
PMID 37160401, PMID 37811598, PMID 16215338, PMID 16616268, PMID 18654615, PMID 19380256, PMID 23424164, PMID 23554851, PMID 24246044, PMID 26376691, PMID 28850362, PMID 34988092, PMID 37148497, PMID 38430402, PMID 41182445